[MOL] Date: Tue, 16 Nov 1999 20:54:29 -0800 [00457] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Date: Tue, 16 Nov 1999 20:54:29 -0800




Warmly, lillian

We invite you to take a look at our Album.
www.angelfire.com/sc/molangels/index.html

  ( Very informational, good tips, Molers pictures, art work and much
more....

----- Original Message -----
From: Mail Delivery Subsystem <MAILER-DAEMON>
To: <firefly@islc.net>
Sent: Thursday, November 11, 1999 5:45 AM
Subject: Returned mail: User unknown


> The original message was received at Wed, 10 Nov 1999 01:21:29 -0500 (EST)
> from pp66.islc.net [208.236.113.66]
>
>    ----- The following addresses had permanent fatal errors -----
> <mol-cancer@lists.meds.com>
>
>    ----- Transcript of session follows -----
> ... while talking to lists.meds.com.:
> >>> RCPT To:<mol-cancer@lists.meds.com>
> <<< 550 <mol-cancer@lists.meds.com>... Relaying denied
> 550 <mol-cancer@lists.meds.com>... User unknown
>

ATT00314.dat


---- Begin included message ----
"Cancer Chemotherapy: A Nursing Process Approach," 2nd Edition, by M. Burke, G. Wilkes, K. Ingwersen, C. Bean and D. Berg., Jones and Bartlett Publishing. An overview of the cognitive affects of chemotherapy.
Journal of the National Cancer Institute
http://www.jnci.oupjournals.org
vol. 90, no. 3, February 4, 1999. There are two articles related to "Chemobrain" in this issue of the JNCI. You can get a copy at your local library or visit the website and read the selected abstracts. The articles are titled, "Cognitive Dysfunction Following Adjuvant Treatment of Breast Cancer: a New Dose-Limiting Toxic Effect?" and "Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy"
Warmly, lillian
 
We invite you to take a look at our Album.                                               
www.angelfire.com/sc/molangels/index.html
 
  ( Very informational, good tips, Molers pictures, art work and much more....
---- End included message ----